Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Inflammation 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1Autoimmune Diseases 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1237Docetaxel 1227Oxaliplatin 1184Capecitabine 1176Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 898Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 639Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Ashwagandha × Clear all
NCT05610735 2026-03-19

Combination Therapy for Recurrent Ovarian Cancer

University of Louisville

Phase 1/2 Recruiting
72 enrolled
Gynecologic

Ovarian Neoplasms

NCT04092647 2023-06-15

Ashwagandha for Cognitive Dysfunction

Sutter Health

Phase 2 Unknown
80 enrolled

Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction

NCT00817752 2010-03-18

Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation

National University of Natural Medicine

Phase 1 Completed
25 enrolled

Autoimmune Diseases, Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡